Pharmaceuticals

Neutralizing Antibody Market Outlook 2026–2030 Driven By Growth Factors And Projections

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Neutralizing Antibody Market Expected To Scale Between 2026 And 2030?

The neutralizing antibody market size has experienced rapid growth over recent years. It is anticipated to expand from $257.81 billion in 2025 to $288.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.9%. Historically, this growth can be ascribed to factors such as the emergence of viral outbreaks like sars-cov-2, the development of early monoclonal antibody platforms, increasing research and development in immunology, the adoption of antibodies in diagnostic assays, and the reliance on animal-derived polyclonal antibodies.

The neutralizing antibody market size is anticipated to experience rapid growth in the upcoming years, with projections indicating an increase to $447.16 billion by 2030, at a compound annual growth rate (CAGR) of 11.6%. This expansion during the forecast period can be attributed to advancements in fully human and humanized monoclonal antibodies, the growth of recombinant polyclonal antibody technology, escalating global demand for covid-19 and influenza therapeutics, increasing collaboration between pharma and biotech companies, and the expansion of antibody research in emerging markets. Significant trends for the forecast period include rising investment in neutralizing antibody therapeutics, the broadened development of monoclonal and polyclonal antibodies, increasing applications in viral diagnostics and research, a growing focus on personalized medicine and targeted therapies, and enhanced regulatory oversight and compliance for antibody production.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24620&type=smp

Which Strong Drivers Are Impacting The Neutralizing Antibody Market Growth?

The escalating occurrence of infectious diseases is projected to boost the expansion of the neutralizing antibody market moving ahead. Infectious diseases are defined as illnesses resulting from detrimental microorganisms, including bacteria, viruses, fungi, or parasites, capable of direct or indirect transmission between individuals. This increase in the prevalence of such diseases is attributed to greater travel, which aids the swift dissemination of pathogens across different regions. Neutralizing antibodies improve the treatment of infectious diseases by precisely targeting and impeding pathogens, thereby proving effective in halting disease advancement. They contribute to better patient outcomes through accurate and prompt immune defense. As an illustration, in February 2024, the UK Health Security Agency, a UK-based government body, reported that tuberculosis cases in England, a communicable bacterial infection primarily affecting the lungs, escalated to 4,850 in 2023, marking an increase of 10.7% from 4,380 cases recorded in 2022. Consequently, the growing prevalence of infectious diseases is a key factor stimulating the growth of the neutralizing antibody market.

How Is The Neutralizing Antibody Market Categorized Across Its Segment Groups?

The neutralizing antibody market covered in this report is segmented –

1) By Antibody Type: Monoclonal Antibodies, Polyclonal Antibodies

2) By Target Virus: SARS-CoV-2 (COVID-19), Human Immunodeficiency Viruses (HIV), Influenza, Ebola, Zika, Hepatitis C, Other Target Viruses

3) By Distribution Channel: Direct Sales To End-Users, Distributors, Online Retail, Other Distribution Channels

4) By Application: Therapeutics, Diagnostics, Research And Development

5) By End User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Murine Monoclonal Antibodies

2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies, Recombinant Polyclonal Antibodies, Human Polyclonal Antibody Preparations

Which Trends Are Influencing Demand In The Neutralizing Antibody Market?

Major companies within the neutralizing antibody market are actively concentrating on developing innovative solutions, such as long-acting monoclonal neutralizing antibodies. These efforts aim to deliver sustained protection against infectious diseases, address critical medical needs in vulnerable populations, and overcome existing limitations associated with traditional vaccines. Long-acting monoclonal neutralizing antibodies are specifically engineered proteins that bind viral antigens with high affinity to block infection, while modifications in their Fc region extend their half-life within the body. Unlike conventional small-molecule antivirals or vaccines, these antibodies provide passive immunity without necessitating repeated dosing or an active immune response. For example, in June 2025, Merck & Co. Inc, a US-based pharmaceutical company, introduced clesrovimab-cfor, a long-acting monoclonal neutralizing antibody approved by the U.S. FDA. This fully human IgG1? antibody targets the fusion (F) protein of respiratory syncytial virus (RSV) and features a triple amino acid substitution in its Fc region to enhance binding to the neonatal Fc receptor and prolong serum half-life. Administered as a single 105 mg intramuscular dose, independent of infant weight, it offers season-long protection against RSV, thereby supporting preventive care for infants and high-risk populations.

Which Firms Are Influencing Competition In The Neutralizing Antibody Market?

Major companies operating in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, AXIM Biotechnologies.

Get The Full Neutralizing Antibody Market Report:

https://www.thebusinessresearchcompany.com/report/neutralizing-antibody-global-market-report

Which Region Is The Leading Market For The Neutralizing Antibody Market?

North America was the largest region in the neutralizing antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neutralizing antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neutralizing Antibody Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neutralizing-antibody-global-market-report

Browse Through More Reports Similar to the Global Neutralizing Antibody Market 2026, By The Business Research Company

Immune Health Supplements Market Report 2026

https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795